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INTRODUCTIONANDAIMS:Hyperkalaemia is associated with adverse clinical out-
comes in patients with chronic kidney disease (CKD). This real-world analysis investi-
gated the incidence and recurrence of hyperkalaemia in incident CKD stage 3þ
patients in the UK, and the excess length-of-stay andmortality of these patients follow-
ing admission to hospital.
METHODS: This retrospective observational cohort study utilised patient records
from the Clinical Practice Research Datalink andHospital Episodes Statistics (HES),
from Jan 2006 to Dec 2015. Patients with eGFR &#8804;60mL/min/1.73m2 or a diagno-
sis/admission code for CKD stage 3þ during the study period were included. Patients
with a history of CKD or heart failure prior to the study period were excluded, or if dial-
ysis was their first renal event. A hyperkalaemia episode was defined as a serum potas-
siummeasurement5.0 mmol/L, without a similar measurement in the preceding
seven days. Median time between successive hyperkalaemia episodes was quantified
among patients experiencing the given number of episodes (ignoring censoring).
Hospital admissions in hyperkalaemic patients were matched to those in non-hyperka-
laemic patients on age, gender and primary diagnosis. Differences in mean length-of-
stay and odds ratios associated with in-hospital/30-day-post-discharge mortality
between the two groups were estimated using Generalised Estimating Equations.
RESULTS: A total of 306,569 hyperkalaemia episodes were observed in 191,964
patients, at a rate of 321.9 episodes per 1,000 patient-years (95% confidence interval:
320.7-323.0). Hyperkalaemia was experienced by 48.4% of the cohort, with 28.8%
experiencingmultiple episodes. The probability of multiple episodes increased with
renal function decline, and was greater for females thanmales, patients with diabetes
than those without, and patients in receipt of RAASi than those not in receipt (all
p<0.0001). The median time from initial CKD event to first hyperkalaemia episode
(among patients who experienced at least one episode) was 1.7 years, falling to 0.9 years
from first to second episode, 0.6 years from second to third episode, and 0.5 years from
third to fourth episode. HES records could be linked to 99,995 patients; mean length-
of-stay among 55,439 hospital admissions of hyperkalaemic patients was 10.6 days,
3.5% longer than in the matched non-hyperkalaemic cohort (p<0.0001), and increas-
ing to 12.9% (p¼0.0003) for severe hyperkalaemia (6.0 mmol/L). The odds of in-hos-
pital/post-discharge mortality was 20% greater for patients with hyperkalaemia
(p<0.0001).
CONCLUSIONS: Recurrent hyperkalaemia was common among incident CKD stage
3þ patients in the UK. Hyperkalaemia was more frequent after each successive episode,
with increasingly shorter intervals between episodes. Hospitalised patients with hyper-
kalaemia tended to remain in hospital longer than those without hyperkalaemia, there-
fore placing a greater burden on the healthcare system, and were more likely to die
during or shortly after the admission.
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INTRODUCTIONANDAIMS:Chronic kidney disease patients have a higher risk of
suffering from cardiovascular diseases such as hypertension and hyperlipidemia.
Hypertension and chronic kidney disease are related, and uncontrolled hypertension
increases the risk of progression in chronic kidney disease. 50% of patients suffering
from a chronic disease are non-adherent, which is associated with inadequate disease
control. The aim of this study is to investigate and explore adherence and beliefs about
medicine among chronic kidney disease patients in treatment with antihypertensives or
lipid-lowering drugs.
METHODS: Amixed methods approach was used combining questionnaires and
semi-structured interviews. Patients aged over 18 with a chronic kidney disease were
included. The questionnaire included Beliefs about Medicine Questionnaire (BMQ) to
measure beliefs and DanishMedication Adherence Report Scale (D-MARS) to measure
adherence. Qualitative semi-structured interviews were conducted to explore attitude,
perception, and knowledge about medicine. Transcripts were systematically themed
and condensed.
RESULTS: 86 participants completed the questionnaire and were included in the statis-
tical analysis. The average age of the participants was 60.3 years (SD6 11.3). Of partici-
pants in treatment with antihypertensives, 85.4 % had high adherence, whereas 87.2 %
of participants in treatment with lipid-lowering drugs had high adherence. Medium/
low adherers had significant lower age than high adherers and were more concerned
about their treatment. 13 of the 86 participants who answered the questionnaire were
interviewed and included in the qualitative analysis. The appearing themes were
mapped against a theoretical framework of this study which was derived mainly from
The five dimensions of adherence proposed by theWorld Health Organization. The
main themes were patient-related factors (disease andmedicine knowledge, health and
disease perception, attitude towards medicine, self-management, disease andmedicine
concerns), therapy- and condition-related factors (side effects and asymptomatic dis-
ease), health care team and system-related factors (patient-physician relationship), and
social and economic factors (family support).
CONCLUSIONS: Patient-related factors were the most prominent themes among the
interviewed participants. Concerns about medicine and younger age were associated
with non-adherence. Concerns were identified as fears of side effects and drug
interactions.
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INTRODUCTIONANDAIMS: Little is known about the burden of hospitalisations in
non end-stage chronic kidney disease (CKD).We assessed hospitalisation rates, dura-
tion, and causes in patients with moderate and advanced CKD under nephrology care.
METHODS: The CKD-REIN study is a prospective cohort which included 3033 outpa-
tients (65%men) with CKD and estimated glomerular filtration rate (eGFR) of 15-60
mL/min per 1.73 m2 at 40 nationally representative public and private nephrology clin-
ics in France. Hospitalisations with at least 1 night, day-hospitalisations, and emer-
gency visits were recorded over a 2-yr follow-up.
RESULTS:At baseline, patients’ median age was 69 (IQR, 60-76), their mean eGFR was
33mL/min per 1.73 m2, and 36% had albuminuria> 30mg/mmol (or proteinuria
>50). Distribution of cohort participants according to KDIGO 2012
eGFR*albuminuria risk categories and prevalence of comorbidities are shown in the
Table below. Over 2-yr follow-up, there were 282 deaths and 380 ESRD. A total of 4978
hospitalisations occurred before ESRD of which 2648 1 night, i.e., 24.3 [95%CI,
22.9-25.7] per 100 person-years. Median number of hospitalisations 1 night per
patient was 2[IQR, 1-3]; their median duration was 5[IQR, 3-11] days. The twomost
common causes of hospitalisation were cardiovascular disease (24%), mainly cardiac
failure, and acute kidney injury (13%). CKD risk category, comorbidities, and care in
public vs private nephrology clinics were significantly associated with higher hospital-
isation risks (Table).
CONCLUSIONS: The burden of hospitalisation is high in patients with CKD under
nephrology care and strongly related to CKD severity and associated comorbidities.
Consequences of this high number of hospitalisations is under evaluation
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